Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

g which the Court will render its final order.  We look forward to a resolution of these next steps and to SIGA's successful commercialization of ST-246, which has the opportunity for additional U.S. government procurement contracts."

Third Quarter Financial ResultsFor the third quarter of 2011 PharmAthene recognized revenue of $5.3 million compared to $6.2 million in the same period of 2010.  Revenues for the most recent quarter consisted of contract funding from the U.S. government for the development of the Company's SparVax™ and Valortim® biodefense programs.  

Revenues for the Company's SparVax™ program were $4.3 million for the three months ended September 30, 2011 compared to $3.8 million for the same period in 2010.  The increase in revenue for the Company's SparVax™ program is primarily attributable to additional work conducted in relation to the technology transfer process for SparVax™ to a US-based contract manufacturer and related milestone payments.

Revenues for the Company's Valortim® program were $0.9 million for the third quarter of 2011 compared to $0.6 million for the same period in 2010. The increase in revenues for SparVax™ and Valortim® during this period was offset by a decrease in Protexia® revenue resulting from the completion of PharmAthene's contract with the Department of Defense (DoD) in 2010.

Research and development expenses were $4.9 million for the quarter ended September 30, 2011 compared to $6.2 million for the same period in 2010.  The year-over-year difference in research and development expenses were primarily due to the decrease in development expenses related to the completion of the bioscavenger contract with the DoD.

General and administrative expenses were $3.3 million and $3.2 million for the quarters ended September 30, 2011 and 2010, respectively.

For the third quarter of 2011 PharmAthene's net loss att
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 VG Energy, ... alliance with DAK Renewable Research to conduct field ... yield. VG Energy is a majority owned subsidiary ... VG Energy,s exclusively licensed compound LipidMax ... oil yield in plants, possessing a wide variety ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 ... made trips to supermarkets to search for the ... grocery store aisles. Results from a year long study ... bacteria level in foods, specifically meats, over previous years. ... explains how the growth of antibiotic resistant bacteria in ...
(Date:5/23/2013)... BETHESDA, Md. , May 23, 2013 ... a biotechnology company developing DCVax ® personalized immune ... will use its exhibit at this year,s American Society ... to highlight its leadership role in immune ... The ASCO annual meeting is the pre-eminent conference ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it ... and Drug Administration (FDA) for the Elecsys Anti-HBc IgM assay for ... 601 and MODULAR ANALYTICS E170 analyzers. ... panel within the hepatitis menu on Roche,s family of immunoassay analyzers. ...
... Selexis SA , a global life science company with ... manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL ... the preclinical development of a therapeutic antibody anticipated ... This commercial license agreement provides CSL with the rights to ...
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
Cached Biology Technology:Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval 2CSL Limited Signs Commercial License Agreement with Selexis SA 2Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2
... from the electrical signals emitted by diverse brain cells ... level, scientists struggle to explain the mind. Worse yet, ... in patients with ailments such as depression or Parkinson's ... issue of Nature describes a technique to directly control ...
... found early indicators of inflammation ?potential warning signs ?in ... findings could someday lead to early detection and prevention ... tendonitis. , The new study from Temple University ... doctoral student, Stephen Carp, in the March issue of ...
... for Cancer Research (LICR) and the University of California, ... breakthrough in identifying functional elements in the human genome, ... Genetics. , While the DNA sequence can identify ... the more fundamental questions of 'how,' 'when' and 'where' ...
Cached Biology News:A 'traffic light' for neurons means 'go' for improving brain research 2A 'traffic light' for neurons means 'go' for improving brain research 3A 'traffic light' for neurons means 'go' for improving brain research 4Red flag for repetitive stress injuries identified for first time in humans 2Beyond the DNA: Chemical signatures reveal genetic switches in the genome 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: